טוען...
Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience
Ibrutinib is highly effective in patients with relapsed or refractory mantle cell lymphoma (MCL) in major clinical trials. Although there has been a dramatic improvement in survival outcomes in the salvage setting, nonresponders to ibrutinib have a bleak prognosis. Therefore, this retrospective stud...
שמור ב:
| הוצא לאור ב: | Cancer Med |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6853811/ https://ncbi.nlm.nih.gov/pubmed/31560165 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2565 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|